Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

Vertex is also developing a version called VX-264 in which the cells are encapsulated in a protective device designed to protect them from rejection by the immune system. A phase 1/2 trial of VX ...